Human Genome Sciences Patent-Cliff Exposure & CMS Drug Spending Portfolio

Human Genome Sciences (US): 1 reconciled FDA prescription therapies, $446.1M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$446.1M
2024 Medicare Part D Spend$216.8M
2024 Medicaid Spend$229.3M
California HCAI SB 17 Filings8 WAC filings (max 21.6% 2-yr change)